Published in Bone on December 10, 2016
Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med (2014) 6.56
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet (2001) 5.72
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet (2001) 4.97
Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem (2007) 4.74
Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res (2009) 3.69
Biomechanical and molecular regulation of bone remodeling. Annu Rev Biomed Eng (2006) 3.46
Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest (2006) 3.45
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology (2005) 3.42
Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone. Proc Natl Acad Sci U S A (2015) 2.25
Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab (2010) 2.05
Secreted and transmembrane wnt inhibitors and activators. Cold Spring Harb Perspect Biol (2013) 2.01
Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res (2011) 2.00
In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res (2014) 1.90
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res (1998) 1.85
Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction. Sci Transl Med (2016) 1.75
Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res (2012) 1.55
Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res (2011) 1.53
Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone. J Endocrinol Invest (2012) 1.43
Exercise training in obese older adults prevents increase in bone turnover and attenuates decrease in hip bone mineral density induced by weight loss despite decline in bone-active hormones. J Bone Miner Res (2011) 1.32
Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab (2012) 1.27
Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab (2011) 1.26
Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH. J Biol Chem (2013) 1.23
Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res (2011) 1.23
Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol (2007) 1.19
Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. Bone (2011) 1.19
Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol (2010) 1.19
Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J Clin Endocrinol Metab (2013) 1.14
Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int (2012) 1.13
Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res (2011) 1.11
Weight loss in obese older adults increases serum sclerostin and impairs hip geometry but both are prevented by exercise training. J Bone Miner Res (2012) 1.08
Association between sclerostin and bone density in chronic spinal cord injury. J Bone Miner Res (2012) 1.07
Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Res (2011) 1.05
The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol (2013) 1.03
Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. Bone (2013) 1.02
Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. J Clin Endocrinol Metab (2012) 1.02
Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. Int J Cancer (2011) 1.01
Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study. Osteoporos Int (2011) 1.00
Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study. J Clin Endocrinol Metab (2012) 1.00
Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays. J Clin Endocrinol Metab (2011) 0.99
Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J (2011) 0.99
Androgen receptor disruption increases the osteogenic response to mechanical loading in male mice. J Bone Miner Res (2010) 0.98
Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone (2013) 0.97
Circulating sclerostin in disorders of parathyroid gland function. J Clin Endocrinol Metab (2011) 0.96
Acute decline in serum sclerostin in response to PTH infusion in healthy men. J Clin Endocrinol Metab (2011) 0.96
Clinical utility of serum sclerostin measurements. Bonekey Rep (2013) 0.96
Sclerostin is overexpressed by plasma cells from multiple myeloma patients. Ann N Y Acad Sci (2011) 0.94
Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover. Bone (2012) 0.93
Serum sclerostin increases in healthy adult men during bed rest. J Clin Endocrinol Metab (2012) 0.93
Sclerostin levels during growth in children. Osteoporos Int (2011) 0.93
The Wnt Inhibitor Sclerostin Is Up-regulated by Mechanical Unloading in Osteocytes in Vitro. J Biol Chem (2015) 0.93
Sclerostin and DKK1 in primary hyperparathyroidism. Calcif Tissue Int (2013) 0.92
Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA (2015) 0.92
Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporos Int (2011) 0.91
Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical cAMP/PKA Pathways. J Bone Miner Res (2015) 0.90
Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels. Proc Natl Acad Sci U S A (2014) 0.90
Circulating sclerostin is elevated in short-term and reduced in long-term SCI. Bone (2012) 0.90
Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone (2013) 0.90
Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin Pract (2014) 0.89
Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells. Biochem Biophys Res Commun (2015) 0.89
From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD. Pediatr Nephrol (2015) 0.89
Sclerostin and DKK1 levels during 14 and 21 days of bed rest in healthy young men. J Musculoskelet Neuronal Interact (2013) 0.89
The sclerostin-independent bone anabolic activity of intermittent PTH treatment is mediated by T-cell-produced Wnt10b. J Bone Miner Res (2014) 0.88
Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study. J Bone Miner Res (2015) 0.88
Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels. J Bone Miner Res (2013) 0.87
Sclerostin and Pref-1 have differential effects on bone mineral density and strength parameters in adolescent athletes compared with non-athletes. Osteoporos Int (2013) 0.87
Odanacatib: location and timing are everything. J Bone Miner Res (2012) 0.86
Teriparatide increases bone formation and bone mineral density in adult women with anorexia nervosa. J Clin Endocrinol Metab (2014) 0.86
Sclerostin blood levels before and after kidney transplantation. Kidney Blood Press Res (2014) 0.86
Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls. Bone (2012) 0.85
Determinants of bone strength and quality in diabetes mellitus in humans. Bone (2015) 0.85
Sclerostin levels and changes in bone metabolism after bariatric surgery. J Clin Endocrinol Metab (2014) 0.85
Androgens inhibit the osteogenic response to mechanical loading in adult male mice. Endocrinology (2015) 0.84
The Sirtuin1 activator SRT3025 down-regulates sclerostin and rescues ovariectomy-induced bone loss and biomechanical deterioration in female mice. Endocrinology (2014) 0.84
Effect of supplemental vitamin D and calcium on serum sclerostin levels. Eur J Endocrinol (2014) 0.84
New Insights Into Androgen and Estrogen Receptor Regulation of the Male Skeleton. J Bone Miner Res (2015) 0.83
Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin. J Bone Miner Res (2016) 0.83
Bone marrow plasma macrophage inflammatory protein protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics. Leuk Res (2014) 0.82
Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus. Clin Endocrinol (Oxf) (2013) 0.82
Uremic toxicity and sclerostin in chronic kidney disease patients. Nephrol Ther (2014) 0.82
Increased sclerostin and preadipocyte factor-1 levels in prepubertal rhythmic gymnasts: associations with bone mineral density, body composition, and adipocytokine values. Osteoporos Int (2015) 0.81
Effects of Age and Estrogen on Skeletal Gene Expression in Humans as Assessed by RNA Sequencing. PLoS One (2015) 0.81
Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids. Osteoporos Int (2013) 0.81
TNF-α mediates the stimulation of sclerostin expression in an estrogen-deficient condition. Biochem Biophys Res Commun (2012) 0.80
Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. J Clin Endocrinol Metab (2012) 0.80
Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures. Osteoporos Int (2015) 0.80
Can we compare serum sclerostin results obtained with different assays in hemodialysis patients? Int Urol Nephrol (2015) 0.80
Hyperthyroidism and Hypothyroidism in Male Mice and Their Effects on Bone Mass, Bone Turnover, and the Wnt Inhibitors Sclerostin and Dickkopf-1. Endocrinology (2015) 0.80
Differential sclerostin and parathyroid hormone response to exercise in boys and men. Osteoporos Int (2015) 0.79
Successful treatment of thyrotoxicosis is accompanied by a decrease in serum sclerostin levels. Thyroid Res (2012) 0.79
Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease. J Bone Miner Res (2016) 0.79
Alterations in vitamin D metabolite, parathyroid hormone and fibroblast growth factor-23 concentrations in sclerostin-deficient mice permit the maintenance of a high bone mass. J Steroid Biochem Mol Biol (2014) 0.79
Circulating sclerostin associated with vertebral bone marrow fat in older men but not women. J Clin Endocrinol Metab (2014) 0.78
Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids. Rheumatology (Oxford) (2013) 0.78
Thyrotropin serum levels are differentially associated with biochemical markers of bone turnover and stiffness in women and men: results from the SHIP cohorts. Osteoporos Int (2015) 0.78
Regulation of Sclerostin Production in Human Male Osteocytes by Androgens: Experimental and Clinical Evidence. Endocrinology (2015) 0.77
Bone metabolism and renal stone risk during International Space Station missions. Bone (2015) 0.77
Increase in circulating sclerostin at the early stage of menopausal transition in Japanese women. Maturitas (2015) 0.76
Sclerostin serum levels in patients with systemic autoimmune diseases. Bonekey Rep (2016) 0.76